Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.37 |
| ▸ | ESRRB | O95718 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015871 | 1.00 | NR1H2 (0.37) | NR1H2ESRRBESR1ESRRAESRRG | |
| SCHEMBL10015873 | 1.00 | NR1H2 (0.37) | NR1H2ESRRBESR1ESRRAESRRG | |
| SCHEMBL498751 | 0.86 | NR1H2 (0.38) | NR1H2NR1H3NPC1MAPTRAB9A | |
| SCHEMBL10047133 | 0.80 | NR1H2 (0.44) | NR1H2NR1H3TRPV3ABCB1 | |
| SCHEMBL498896 | 0.80 | NR1H2 (0.49) | NR1H2NR1H3TRPV3ABCB1 | |
| SCHEMBL498984 | 0.80 | NR1H2 (0.43) | NR1H2NR1H3TRPV3ABCB1 | |
| SCHEMBL10015878 | 0.73 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL10047137 | 0.71 | NR1H2 (0.42) | NR1H2NR1H3TRPV3ABCB1 | |
| SCHEMBL499554 | 0.71 | NR1H2 (0.42) | NR1H2ESRRBESR1ESRRAESRRG | |
| SCHEMBL5176211 | 0.66 | GCGR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| EP-1751100-B1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | CENTRE NAT RECH SCIENT (FR) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | TUBB1, TUBB3, TUBB | NR1H2 1515/4885ESRRB 4719/4885ESR1 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.